Understanding Tysabri and PML: What Patients Should Discuss with Their Doctor

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Occupational Risk

If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML). This serious brain infection has been linked to the medication, prompting important updates from the FDA. Building on decades of research into biologic therapies, this page provides a clear overview of the PML warning and what it means for treatment decisions.

Medical Evidence Linking Tysabri to PML

The association between Tysabri (natalizumab) and progressive multifocal leukoencephalopathy (PML) is a well-documented medical risk that has significant implications for patients and their legal representatives. PML is an opportunistic viral infection of the brain caused by the JC virus, typically occurring only in immunocompromised individuals, and it usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Tysabri, stating that the drug increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is prominently displayed in the prescribing information to alert healthcare professionals and patients to the serious nature of this adverse effect. Clinical presentation and diagnosis of PML are critical for early detection and management. Symptoms may include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and visual changes. The FDA Adverse Event Reporting System (FAERS) data for Tysabri frequently list fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, and balance disorder among the most common adverse events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms can overlap with multiple sclerosis itself, any new or worsening neurological signs should prompt immediate evaluation for PML. Diagnosis typically involves brain imaging, such as MRI, and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction (PCR).

Pharmacology and Risk Factors for PML

The pharmacology of Tysabri involves its action as an alpha-4 integrin antagonist, which prevents immune cells from crossing the blood-brain barrier. This mechanism reduces inflammation in the central nervous system but also impairs immune surveillance, allowing latent JC virus to reactivate and cause PML. Three key risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The mechanistic pathway linking Tysabri to PML is well-established. By blocking lymphocyte migration into the brain, Tysabri reduces the immune system's ability to control JC virus replication. This leads to lytic infection of oligodendrocytes, resulting in demyelination and the characteristic lesions of PML. The timeline between exposure to Tysabri and documented harm can vary, but cases have been reported after a few months to several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The risk increases with duration, particularly beyond two years, and in patients who are anti-JCV antibody positive.

Adequacy of Warnings and Legal Implications

Adequacy of warnings regarding Tysabri and PML is a central issue for affected patients. The FDA boxed warning clearly states that Tysabri increases the risk of PML and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to read the Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether patients were adequately informed of the risk, especially if they developed PML without clear documentation of risk factor assessment or monitoring. Attorney-related considerations for affected patients in Pennsylvania involve the statute of limitations for filing a claim. In Pennsylvania, the statute of limitations for personal injury cases, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or should have been discovered. For PML, this date may be when the diagnosis was confirmed or when symptoms first appeared that led to the diagnosis. Given the progressive nature of PML and the potential for delayed diagnosis, it is crucial for patients and their families to consult with an attorney promptly to ensure their legal rights are preserved. The timeline between exposure to Tysabri and documented harm is a key factor in determining when the statute of limitations begins to run.

Conclusion and Next Steps

In summary, the medical evidence clearly establishes that Tysabri increases the risk of PML, a severe and often fatal brain infection. The FDA has mandated warnings and a restricted distribution program to mitigate this risk, but affected patients may still face significant harm. For those in Pennsylvania, understanding the statute of limitations and seeking legal advice promptly is essential. The combination of clinical presentation, pharmacological mechanism, and risk factors provides a strong foundation for evaluating potential claims related to Tysabri-associated PML.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Pennsylvania?

In Pennsylvania, the statute of limitations for personal injury cases, including those related to pharmaceutical products like Tysabri, is generally two years from the date the injury was discovered or should have been discovered. For PML, this date may be when the diagnosis was confirmed or when symptoms first appeared that led to the diagnosis. It is crucial to consult with an attorney promptly to preserve your legal rights.

What are the key risk factors for developing PML while taking Tysabri?

Three key risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when evaluating the risk of PML in Tysabri-treated patients.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.